The UPF3A antibody is a crucial tool for studying the UPF3A protein, a key component of the nonsense-mediated mRNA decay (NMD) pathway. UPF3A, along with its paralog UPF3B, plays a role in degrading mRNAs containing premature termination codons to prevent the production of truncated proteins. While UPF3B is widely studied and linked to neurodevelopmental disorders, UPF3A is less characterized but is thought to act redundantly or complementarily in NMD, particularly in tissues where UPF3B is less expressed. Antibodies targeting UPF3A enable researchers to investigate its expression, subcellular localization (primarily nuclear-cytoplasmic shuttling), and interactions with other NMD factors like UPF2 and the exon junction complex. These antibodies are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to explore UPF3A’s role in cellular quality control, gene regulation, and diseases like cancer or neurological conditions. Commercially available UPF3A antibodies are typically raised in hosts like rabbits or mice, validated for specificity via knockout/knockdown controls. Research using these antibodies has provided insights into UPF3A’s compensatory upregulation in UPF3B-deficient models, highlighting its potential therapeutic relevance. However, challenges remain in distinguishing UPF3A-specific functions due to overlapping roles with UPF3B.